Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Accumulated Expenses (2021 - 2025)

Prime Medicine (PRME) has disclosed Accumulated Expenses for 5 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 20.77% year-over-year to $12.6 million, compared with a TTM value of $12.6 million through Dec 2025, down 20.77%, and an annual FY2025 reading of $12.6 million, down 20.77% over the prior year.
  • Accumulated Expenses was $12.6 million for Q4 2025 at Prime Medicine, up from $11.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $37.2 million in Q4 2021 and bottomed at $6.5 million in Q3 2022.
  • Average Accumulated Expenses over 5 years is $15.0 million, with a median of $12.4 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses crashed 71.26% in 2022, then surged 32.02% in 2023.
  • Year by year, Accumulated Expenses stood at $37.2 million in 2021, then plummeted by 71.26% to $10.7 million in 2022, then skyrocketed by 32.02% to $14.1 million in 2023, then increased by 12.71% to $15.9 million in 2024, then dropped by 20.77% to $12.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for PRME at $12.6 million in Q4 2025, $11.0 million in Q3 2025, and $12.2 million in Q2 2025.